Celcuity Launches REVTORPYK Commercially in US for Advanced Breast Cancer

Key Facts

1Celcuity announced the commercial availability of REVTORPYK (gedatolisib) in the United States for specific advanced breast cancer patients.

2REVTORPYK is the first FDA-approved therapy to inhibit all class I PI3K isoforms and mTOR complexes.

Celcuity announced the commercial availability of REVTORPYK (gedatolisib) in the United States for specific advanced breast cancer patients. According to a statement via GlobeNewswire, REVTORPYK is the first FDA-approved therapy to inhibit all class I PI3K isoforms and mTOR complexes, offering a new targeted treatment option for patients facing disease progression.

CELC closed at $77.38 on September 29, 2026, with the stock reaching a day high of $80.52 and a low of $77.25 during that session. The commercial launch follows clinical trial results demonstrating that the drug significantly reduced the risk of disease progression or death in patients with HR+/HER2- advanced breast cancer.